Compounds > 17-ethinyl-7 alpha-methyl-19-nortestosterone
Page last updated: 2024-11-13

17-ethinyl-7 alpha-methyl-19-nortestosterone

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

delta(4)-tibolone: metabolite of tibolone; has progestational activity without estrogenic activity seen in tibolone [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID22814761
SCHEMBL ID2835215
MeSH IDM0043152

Synonyms (33)

Synonym
19-nor-17-alpha-preg-4-en-20-yn-3-one, 17-hydroxy-7-alpha-methyl-
17-ethinyl-7-alpha-methyl-19-nortestosterone
brn 4263193
7-alpha-methyl-17-ethinyl-19-nortestosterone
19-norpregn-4-en-20-yn-3-one, 17-hydroxy-7-methyl-, (7alpha,17alpha)-
17-hydroxy-7-alpha-methyl-19-nor-17-alpha-preg-4-en-20-yn-3-one
nsc 142228
delta(4)-tibolone
1162-60-3
17-ethynyl-17-hydroxy-7,13-dimethyl-1,2,6,7,8,9,10,11,12,14,15,16-dodecahydrocyclopenta[a]phenanthren-3-one
unii-lhz8r2ow0m
isotibolone
7alpha-methylnorethindrone
lhz8r2ow0m ,
org-om 38
delta4-tibolone
SCHEMBL2835215
19-norpregn-4-en-20-yn-3-one, 17-hydroxy-7-methyl-, (7.alpha.,17.alpha.)-
DTXSID10921959
(7alpha,17beta)-17-ethynyl-17-hydroxy-7-methylestr-4(5)en-3-one
(7alpha,17beta)-17-ethynyl-17-hydroxy-7-methylestr-4(5)en-3- one
(7r,8r,9s,10r,13s,14s,17r)-17-ethynyl-17-hydroxy-7,13-dimethyl-1,2,6,7,8,9,10,11,12,14,15,16-dodecahydrocyclopenta[a]phenanthren-3-one
isotibolone; delta4-tibolone; 17-hydroxy-7?-methyl-19-nor-10?,17?-pregn-4-en-20-yn-3-one
tibolone ep impurity c
7.alpha.-methylnorethisterone
7.alpha.-methyl-17.alpha.-ethynyl-19-nortestosterone
7.alpha.-methylnorethindrone
org-om-38
.delta.4-tibolone
(7.alpha.,17.alpha.)-17-hydroxy-7-methyl-19-norpregn-4-en-20-yn-3-one
?4-tibolone
nsc816239
nsc-816239

Research Excerpts

Dosage Studied

ExcerptRelevanceReference
" In plasma, the predominant nonsulfated metabolite after single and multiple dosing was the estrogenic 3alpha-hydroxytibolone; levels of the estrogenic 3beta-hydroxytibolone were 10-fold lower and of progestagenic/androgenic Delta(4)-tibolone, 5-fold lower."( Pharmacokinetic parameters of tibolone and metabolites in plasma, urine, feces, and bile from ovariectomized cynomolgus monkeys after a single dose or multiple doses of tibolone.
Delbressine, LP; Kloosterboer, HJ; Timmer, CJ; van Iersel, ML; Verheul, HA, 2007)		0.34
" Levels of disulfated metabolites in serum and tissues were higher (3- to 5-fold) after multiple dosing than after a single dose."( Levels of tibolone and estradiol and their nonsulfated and sulfated metabolites in serum, myometrium, and vagina of postmenopausal women following treatment for 21 days with tibolone, estradiol, or estradiol plus medroxyprogestrone acetate.
Blok, LJ; Burger, CW; Hanifi-Moghaddam, P; Kloosterboer, HJ; Verheul, HA, 2007)		0.34
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (7)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's5 (71.43)29.6817
2010's2 (28.57)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.94

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.94 (24.57)
Research Supply Index2.40 (2.92)
Research Growth Index4.34 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.94)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials2 (25.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other6 (75.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
estrone
Hydroxyestrones: Estrone derivatives substituted with one or more hydroxyl groups in any position. They are important metabolites of estrone and other estrogens.		4.382217-oxo steroid;
3-hydroxy steroid;
phenolic steroid;
phenols		antineoplastic agent;
bone density conservation agent;
estrogen;
human metabolite;
mouse metabolite
medroxyprogesterone acetate
[no description available]		4.153120-oxo steroid;
3-oxo-Delta(4) steroid;
acetate ester;
corticosteroid;
steroid ester		adjuvant;
androgen;
antineoplastic agent;
antioxidant;
female contraceptive drug;
inhibitor;
progestin;
synthetic oral contraceptive
dihydrotestosterone
Dihydrotestosterone: A potent androgenic metabolite of TESTOSTERONE. It is produced by the action of the enzyme 3-OXO-5-ALPHA-STEROID 4-DEHYDROGENASE.. 17beta-hydroxyandrostan-3-one : A 17beta-hydroxy steroid that is testosterone in which the 4-5 double bond has been reduced to a single bond with unspecified configuration at position 5.. 17beta-hydroxy-5alpha-androstan-3-one : A 17beta-hydroxy steroid that is testosterone in which the 4,5 double bond has been reduced to a single bond with alpha-configuration at position 5.		2.11017beta-hydroxy steroid;
17beta-hydroxyandrostan-3-one;
3-oxo-5alpha-steroid		androgen;
Daphnia magna metabolite;
human metabolite;
mouse metabolite
mifepristone
Mifepristone: A progestational and glucocorticoid hormone antagonist. Its inhibition of progesterone induces bleeding during the luteal phase and in early pregnancy by releasing endogenous prostaglandins from the endometrium or decidua. As a glucocorticoid receptor antagonist, the drug has been used to treat hypercortisolism in patients with nonpituitary CUSHING SYNDROME.		2.11103-oxo-Delta(4) steroid;
acetylenic compound;
tertiary amino compound		abortifacient;
contraceptive drug;
hormone antagonist;
synthetic oral contraceptive
org 31710
Org 31710: structure given in first source; progestational hormone antagonist		2.1110
tibolone
tibolone: used in prevention of postmenopausal osteoporosis. tibolone : Estran-3-one with a double bond between positions 5 and 10, and bearing both an ethynyl group and a hydroxy group at position 17 (R-configuration). A synthetic steroid hormone drug which acts as an agonist at all five type I steroid hormone receptors, it is used in the prevention of postmenopausal osteoporosis and for treatment of endometriosis.		5.246217beta-hydroxy steroid;
terminal acetylenic compound		bone density conservation agent;
hormone agonist
estrone sulfate
estrone sulfate: sulfoconjugated estrone; RN given refers to parent cpd		4.382217-oxo steroid;
steroid sulfate		human metabolite;
mouse metabolite
3-hydroxytibolone
3-hydroxytibolone: tibolone metabolite		4.1131
ConditionIndicatedRelationship StrengthStudiesTrials
Breast Cancer
[description not available]		03.4211
Breast Neoplasms
Tumors or cancer of the human BREAST.		03.4211
Uterine Prolapse
Downward displacement of the UTERUS. It is classified in various degrees: in the first degree the UTERINE CERVIX is within the vaginal orifice; in the second degree the cervix is outside the orifice; in the third degree the entire uterus is outside the orifice.		03.4211